1873.HK Stock Analysis
18
Uncovered
VIVA Biotech Holdings is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Market cap $B
0.162
Dividend yield
0.26 %
Shares outstanding
1 915.44 B
Viva Biotech Holdings engages in the discovery, development, and manufacturing of clinical drugs. The company is headquartered in Shanghai, Shanghai and currently employs 2,309 full-time employees. The company went IPO on 2019-05-09. The firm is principally engaged in the provision of the structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide for their pre-clinical stage innovative drug development. The Company’s core technologies include structure-based drug discovery (SBDD) platform, fragment-based drug discovery (FBDD) platform, affinity selection mass spectrometry (ASMS) screening platform and membrane protein targeted drug discovery platform. The firm operates its businesses mainly in the United States, China, Europe and other regions.